Mr Patrick Hilley
Research Fellow, Gastroenterology
Department of Medicine
29 Scholarly works
0 Projects
HIGHLIGHTS
2026
Journal article
Tacrolimus Bridging and Combination Therapy Following Infliximab and JAK Inhibitor Failure in Ulcerative Colitis: A Case Series
DOI: 10.1002/jgh3.704432026
Journal article
Value‐Based Health Care—Protecting the Future of IBD Care or Pipedream?
DOI: 10.1002/jcc5.700542026
Journal article
Implementation of values-based healthcare in inflammatory bowel disease—a review
DOI: 10.1093/ecco-jcc/jjaf1732025
Journal article
Combination Advanced Therapies for Control of Ulcerative Colitis During Pregnancy
DOI: 10.14309/crj.00000000000019202025
Journal article
Editorial: Redefining Safety in Post-Liver Transplant IBD—Why Therapeutic Effectiveness Is the Ultimate Shield. Authors' Reply
DOI: 10.1111/apt.703412025
Journal article
Systemic Biologics Have Similar Safety to Vedolizumab in Inflammatory Bowel Disease Patients Following Liver Transplantation
DOI: 10.1111/apt.702832025
Conference Proceedings
P66 Systemic biologics have comparable safety to vedolizumab in inflammatory bowel disease patients following liver transplantation
DOI: 10.1136/gutjnl-2025-bsg.202
RECENT SCHOLARLY WORKS
2025
Journal article
How Does an Integrated Pharmacist Add Value in the Management of Inflammatory Bowel Disease in the Era of Values-Based Healthcare?
DOI: 10.1093/ibd/izae1962025
Journal article
P1012 Systemic biologic therapies are associated with comparable safety outcomes to vedolizumab for the management of Inflammatory Bowel Disease following liver transplantation
DOI: 10.1093/ecco-jcc/jjae190.11862024
Journal article
Safety and Effectiveness of Janus Kinase Inhibitors in the Management of Inflammatory Bowel Disease Following Liver Transplantation
DOI: 10.1093/ecco-jcc/jjae039